Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...

GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Citadel has taken a short position worth 305 million pounds ($384.5 million) in GSK stock, representing a 0.51% stake, ...

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...

A clear endorsement from their healthcare provider and being supplied information about recommended vaccines before their ...

Alison Winder has been an assistant editor at the Royal Society of Chemistry since 2022 after several different science-based ...